质子束放射治疗对虹膜黑色素瘤的副作用
该回顾性研究分析了149例接受质子束放射治疗(PBR)作为初次治疗的虹膜黑色素瘤(IM)患者,比较全PBR(wPBR,n=51)与节段PBR(sPBR,n=98)的功能结局和眼部副作用。结果显示wPBR组眼表疾病、继发性青光眼和白内障手术比例均显著高于sPBR组,wPBR组视力在放疗后6个月恶化但12个月恢复,sPBR组无视力下降;作者认为PBR是IM非常成功的治疗选择,肿瘤控制率高且并发症相对较低。
要点
- wPBR组眼表疾病发生率78.4%(40/51)显著高于sPBR组25.5%(25/98)(P < 0.001)。
- wPBR组继发性青光眼发生率31.4%(16/51)显著高于sPBR组1.0%(1/98)(P < 0.001)。
- wPBR组白内障手术比例47.9%(23/48)显著高于sPBR组19.8%(19/96)(P < 0.001)。
核心结论
- 作者认为PBR是虹膜黑色素瘤非常成功的治疗选择,肿瘤控制率高且并发症相对较低。
- 肿瘤复发罕见,任何患者均无需行继发性眼球摘除。
- 副作用常见,但严重副作用如角膜缘干细胞衰竭或继发性青光眼主要发生于wPBR后。
研究设计与样本
- 回顾性研究,分析前瞻性收集的数据。
- 纳入以PBR作为初次治疗的虹膜黑色素瘤患者,共149眼/149例,平均年龄53.9 ± 16.0岁。
- 治疗方式为全PBR(wPBR,n = 51)或节段PBR(sPBR,n = 98)。
主要发现
- 肿瘤复发3例(wPBR:1/51;sPBR:2/98)。
- 眼表疾病见于wPBR组78.4%(40/51)和sPBR组25.5%(25/98)(P < 0.001),分别于0.7 ± 1.2年和1.1 ± 0.9年后出现。
- 两组主要副作用均为干眼综合征,但严重副作用如角膜缘干细胞衰竭仅见于wPBR组(4/51;7.8%)。
- 继发性青光眼发生于wPBR组31.4%(16/51)对比sPBR组1.0%(1/98)(P < 0.001);青光眼一般用眼药水控制,需手术者5例(wPBR:4/51,7.8%;sPBR:1/98,1%)。
- 白内障手术在wPBR组47.9%(23/48)和sPBR组19.8%(19/96)中施行(P < 0.001)。
关键数值与推荐
- 治疗前视力:wPBR组0.14 ± 0.27 logMAR,sPBR组0.04 ± 0.19 logMAR。
- wPBR组放疗后6个月视力恶化至0.55 ± 0.16 logMAR(P < 0.001),12个月后恢复至0.15 ± 0.30 logMAR(P = 0.17)。
- sPBR组未见视力下降(6个月:0.03 ± 0.22 logMAR,P = 0.54;12个月:0.04 ± 0.21 logMAR,P = 0.98)。
临床怎么用
- 作者认为这些结果对临床决策及与患者讨论该放疗方式很重要。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study evaluated the functional outcome and ocular side effects of patients receiving proton beam radiotherapy (PBR) for the treatment of iris melanoma (IM). DESIGN: This retrospective study analyzed prospectively collected data. PARTICIPANTS: Patients with IM who underwent PBR as a primary treatment. METHODS: Treatment was given in the form of whole PBR (wPBR: n = 51) or segmental PBR (sPBR: n = 98). MAIN OUTCOME MEASURES: Visual acuity (VA) and side effects were divided into ocular surface disease (OSD), secondary glaucoma, or cataract development. RESULTS: A total of 149 eyes of 149 patients with a mean age of 53.9 ± 16.0 years were included. Tumor recurrence developed in 3 patients (wPBR: 1/51; sPBR: 2/98). Ocular surface disease was observed in 78.4% of the wPBR group (40/51) and 25.5% of the sPBR group (25/98) (P < 0.001) after 0.7 ± 1.2 years and 1.1 ± 0.9 years, respectively. The main side effect was dry eye syndrome in both groups, but severe side effects such as limbal stem cell failure were found only in the wPBR group (4/51; 7.8%). Secondary glaucoma developed in 31.4% of the wPBR group (16/51) compared with 1.0% in the sPBR group (1/98; P < 0.001). Glaucoma control was generally achieved with eye drops, whereas surgery was necessary in 5 patients (wPBR: 4/51, 7.8%; sPBR: 1/98, 1%). Cataract surgery was performed in 47.9% of the wPBR group (23/48) and 19.8% of the sPBR group (19/96) (P < 0.001). Before treatment, VA was 0.14 ± 0.27 logarithm of the minimum angle of resolution (logMAR) in the wPBR group and 0.04 ± 0.19 logMAR in the sPBR group. A worsening was seen in the wPBR group (0.55 ± 0.16 logMAR; P < 0.001) 6 months after radiotherapy, which normalized after 12 months (0.15 ± 0.30 logMAR; P = 0.17). In the sPBR group, no such decrease in VA was observed (6 months: 0.03 ± 0.22 logMAR, P = 0.54; 12 months: 0.04 ± 0.21 logMAR, P = 0.98). CONCLUSIONS: Our results demonstrate that PBR is a very successful treatment option for patients with IM, showing a high tumor control rate and relatively low complication profile. Tumor recurrence was a rare event, and secondary enucleation was not necessary in any patient. Side effects are commonly seen, but severe side effects such as limbal stem cell failure or secondary glaucoma mainly developed after wPBR. These results are important for clinical decision making and discussion with the patient regarding this form of radiotherapy. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Eibenberger K, Heimann H, Gatchalian L, et al. Side Effects of Proton Beam Radiotherapy Treatment on Iris Melanoma. Ophthalmology. 2023. PMID: 37169262. doi:10.1016/j.ophtha.2023.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。